Portfolio company
Ayuvant
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops RNA nanoparticle immunotherapies to treat cancer patients who do not respond to existing immune checkpoint inhibitors.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Ventuno Biotech
This biotechnology company develops cancer immunotherapies to stimulate the immune system and treat patients with difficult tumours.
THERAtRAME
The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.
Bioarchitech
This company develops viral and RNA immunotherapies designed to help the immune systems of cancer patients target and destroy tumours.
Noara Therapeutics
This company engineers stable and immunosilent ribonucleic acid therapies using machine intelligence to treat patients with chronic and complex diseases.
Avidicure
This biotechnology company develops multifunctional antibody therapies for cancer patients to activate immune responses while reducing toxicity.
Axelyf
The company develops lipid nanoparticle delivery systems and RNA therapeutics for pharmaceutical developers and patients with oncology or autoimmune diseases.
Kovina Therapeutics
The company develops antiviral therapies to treat cancers and pre-malignant infections caused by Human Papillomavirus for patients with existing infections.
Capstan Therapeutics
Capstan Therapeutics develops in vivo RNA-based therapies for patients with autoimmune diseases and cancers using targeted lipid nanoparticle technology.